Christine L Barron1,2,3, Louie B Kamel-Abusalha1,2, Rishabh Sethia1,2,3, Steven D Goodman1,3, Charles A Elmaraghy2,3, Lauren O Bakaletz1,3. 1. Center for Microbial Pathogenesis, Nationwide Children's Hospital, Columbus, Ohio, U.S.A. 2. Department of Pediatric Otolaryngology-Head and Neck Surgery, Nationwide Children's Hospital, Columbus, Ohio, U.S.A. 3. The Ohio State University College of Medicine, Columbus, Ohio, U.S.A.
Abstract
OBJECTIVES: Otitis media with effusion (OME) is a common disease of childhood that is largely asymptomatic. However, middle ear fluid can persist for months and negatively impact a child's quality of life. Many cases of OME remain chronic and require surgical intervention. Because biofilms are known to contribute to the persistence of many diseases, this study examined effusions collected from children with chronic OME for the presence of essential biofilm structural components, members of the DNABII family of bacterial DNA-binding proteins. METHODS: Middle ear effusions were recovered from 38 children with chronic OME at the time of tympanostomy tube insertion. A portion of each specimen was submitted for microbiology culture. The remaining material was assessed by immunoblot to quantitate individual DNABII proteins, integration host factor (IHF), and histone-like protein (HU). RESULTS: Sixty-five percent of effusions (24 of 37) were culture-positive for bacterial species or yeast, whereas 35% (13 of 37) were culture-negative. IHF was detected in 95% (36 of 38) at concentrations from 2 to 481 ng/μL effusion. HU was detected in 95% (36 of 38) and quantitated from 13 to 5,264 ng/μL effusion (P ≤ 0.05 compared to IHF). CONCLUSION: Because DNABII proteins are essential structural components of bacterial biofilms, these data lend further support to our understanding that biofilms are present in the vast majority of chronic middle ear effusions, despite negative culture results. The presence and ubiquity of DNABII proteins in OME specimens indicated that these proteins can serve as an important clinical target for our novel DNABII-directed strategy to treat biofilm diseases such as chronic OME. LEVEL OF EVIDENCE: NA Laryngoscope, 130:806-811, 2020.
OBJECTIVES:Otitis media with effusion (OME) is a common disease of childhood that is largely asymptomatic. However, middle ear fluid can persist for months and negatively impact a child's quality of life. Many cases of OME remain chronic and require surgical intervention. Because biofilms are known to contribute to the persistence of many diseases, this study examined effusions collected from children with chronic OME for the presence of essential biofilm structural components, members of the DNABII family of bacterial DNA-binding proteins. METHODS:Middle ear effusions were recovered from 38 children with chronic OME at the time of tympanostomy tube insertion. A portion of each specimen was submitted for microbiology culture. The remaining material was assessed by immunoblot to quantitate individual DNABII proteins, integration host factor (IHF), and histone-like protein (HU). RESULTS: Sixty-five percent of effusions (24 of 37) were culture-positive for bacterial species or yeast, whereas 35% (13 of 37) were culture-negative. IHF was detected in 95% (36 of 38) at concentrations from 2 to 481 ng/μL effusion. HU was detected in 95% (36 of 38) and quantitated from 13 to 5,264 ng/μL effusion (P ≤ 0.05 compared to IHF). CONCLUSION: Because DNABII proteins are essential structural components of bacterial biofilms, these data lend further support to our understanding that biofilms are present in the vast majority of chronic middle ear effusions, despite negative culture results. The presence and ubiquity of DNABII proteins in OME specimens indicated that these proteins can serve as an important clinical target for our novel DNABII-directed strategy to treat biofilm diseases such as chronic OME. LEVEL OF EVIDENCE: NA Laryngoscope, 130:806-811, 2020.
Authors: M Elizabeth Brockson; Laura A Novotny; Elaine M Mokrzan; Sankalp Malhotra; Joseph A Jurcisek; Rabia Akbar; Aishwarya Devaraj; Steven D Goodman; Lauren O Bakaletz Journal: Mol Microbiol Date: 2014-08-19 Impact factor: 3.501
Authors: Jodi E Gustave; Joseph A Jurcisek; Karen S McCoy; Steven D Goodman; Lauren O Bakaletz Journal: J Cyst Fibros Date: 2012-11-17 Impact factor: 5.482
Authors: M O Freire; A Devaraj; A Young; J B Navarro; J S Downey; C Chen; L O Bakaletz; H H Zadeh; S D Goodman Journal: Mol Oral Microbiol Date: 2016-04-05 Impact factor: 3.563
Authors: Richard M Rosenfeld; Seth R Schwartz; Melissa A Pynnonen; David E Tunkel; Heather M Hussey; Jeffrey S Fichera; Alison M Grimes; Jesse M Hackell; Melody F Harrison; Helen Haskell; David S Haynes; Tae W Kim; Denis C Lafreniere; Katie LeBlanc; Wendy L Mackey; James L Netterville; Mary E Pipan; Nikhila P Raol; Kenneth G Schellhase Journal: Otolaryngol Head Neck Surg Date: 2013-07 Impact factor: 3.497
Authors: J C Post; R A Preston; J J Aul; M Larkins-Pettigrew; J Rydquist-White; K W Anderson; R M Wadowsky; D R Reagan; E S Walker; L A Kingsley; A E Magit; G D Ehrlich Journal: JAMA Date: 1995 May 24-31 Impact factor: 56.272
Authors: Aishwarya Devaraj; John Buzzo; Christopher J Rocco; Lauren O Bakaletz; Steven D Goodman Journal: Microbiologyopen Date: 2017-12-12 Impact factor: 3.139
Authors: Lauren Martyn; Rishabh Sethia; Rachel Chon; Laura Novotny; Steven D Goodman; Charles Elmaraghy; Lauren O Bakaletz Journal: Laryngoscope Date: 2019-07-17 Impact factor: 3.325
Authors: Henrik Szőke; Márta Maródi; Jan Vagedes; Balázs Székely; István Magyarosi; Adél Bedő; Veronika Fellegi; Krisztina Somogyvári; Péter Móricz Journal: Antibiotics (Basel) Date: 2021-01-30